Beacon Biosignals is a neurotechnology company that brings precision neuroscience into clinical trials and treatments.
Beacon Biosignals has raised $11.0M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Beacon Biosignals's investors include General Catalyst, Alumni Ventures, Samsung NEXT, Catalio Capital Management, Takeda.
Beacon Biosignals is headquartered in Boston, United States.
Beacon Biosignals is a neurotechnology company that brings precision neuroscience into clinical trials and treatments.
Beacon Biosignals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Beacon Biosignals — Funding & Investors." VCBacked, April 6, 2026, https://www.vcbacked.co/company/beacon-biosignals. Accessed September 2, 2026.
VCBacked. (2026). Beacon Biosignals — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/beacon-biosignals
{{cite web |title=Beacon Biosignals — Funding & Investors |url=https://www.vcbacked.co/company/beacon-biosignals |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated